<DOC>
	<DOC>NCT00419536</DOC>
	<brief_summary>This 2-arm study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg twice daily (second arm) and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile.</brief_summary>
	<brief_title>Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Patients with hormone refractory prostate cancer Patients must have metastatic disease with at least 1 measurable soft tissue lesion that can be assessed by CT or MRI and/or detectable lesion(s) on bone scintigraphy scan. Patients with only elevated PSA levels are not eligible for entry. Patients must meet laboratory inclusion criteria defined in the protocol Patients must be able to provide written informed consent Patients with prior or concurrent brain metastases Impaired cardiac, gastrointestinal, kidney or liver function Use of therapeutic androgens Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>LBH</keyword>
	<keyword>LBH589</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
</DOC>